

In the text the drugs are referred to by the names underlined. All the compounds were dissolved in 0.9% saline at the required concentration, except LB-46 which was dissolved in 0.9% saline containing an equimolar quantity of tartaric acid. All doses refer to the salts, except LB-46 which was used as a base.

Spontaneous motor activity (SMA): The method described by Dews (3) was followed in essential details, employing the Asso Automatic Photocell Activity cage, Model 3A. Adult male, albino mice weighing 20-35 g were used. Experiments were performed in a dark and quiet room maintained at a temperature of 20-24°C. To minimise the effect of diurnal variations in SMA, the tests were performed at the same hour each day. Compounds were injected in a dose of 60 mg/kg ip in groups of 5 mice and placed 10 min later on the runway. Counts per 5 mice were recorded every 10 min. for 90 min (nine counts). Mean cumulative activity per 90 min. was also recorded. Control SMA records in 10 mice injected with a matching volume of 0.9% saline ip were similarly taken.

Pentobarbitone induced anaesthesia: Albino mice of either sex weighing 20-30 g were used. An anaesthetic dose of pentobarbitone (60 mg/kg i.p.) was administered to groups of 10 mice. Test compounds in doses ranging between 5 to 70 mg/kg i.p. were administered in groups of 10 mice, 15 min prior to the administration of pentobarbitone in "test groups". Anaesthetic time in min was estimated as the time interval between the loss and the reappearance of the "righting reflex" for each animal. Mean anaesthetic time for the control and the test group was computed. The relative potencies were expressed as the ED₁₀₀ values i.e. the dose inducing a 100% increase in the sleeping time. The ED₁₀₀ values were derived from a semi-logarithmic plot of the doses against the observed anaesthetic time (6). The significance at the dose-step 40 mg/kg i.p. was determined by applying the Student's test at the 5% level (P<0.05).

TABLE I: Effect of some beta-blockers on the SMA of mice. The compounds were administered in a fixed dose of 60 mg/kg ip and movements recorded for 90 min.

Compound*	Mean cumulative activity per 90 min	SMA % of control
—	1545.9 ± 56.6	—
Propranolol	876.4 ± 44.2	56.7
Pronethalol	1712.1 ± 57.5	110.7
d-H56/28	841.4 ± 52.4	54.4
l-H56/28	1185.2 ± 54.2	76.3
Ko-592	1206.5 ± 51.5	78.1
PhQA33	531.4 ± 48.2	34.4
LB-46	829.2 ± 47.5	53.7
DL(±)INPEA	1905.6 ± 55.5	123.2
D(−)INPEA	1780.4 ± 49.3	115.1
L(+)INPEA	1970.2 ± 54.8	127.4

*n = 10 for control and 5 for test values.

Acute intraperitoneal toxicity (LD₅₀): LD₅₀ was determined in adult albino mice of either sex weighing from 20 to 30 g, by the method of Miller and Tainter (9). Test compounds dissolved in saline, in doses graded between 14 and 300 mg/kg in a geometric progression (geometric factor 1.4) were administered ip in groups of 5 mice at each dose level in a volume of 0.1 ml/10 g. The animals were observed and deaths recorded upto 24 hr and 7 days.

RESULTS

It was observed that both in the control and test groups of mice, the SMA was high initially and declined later on. Propranolol, d-H56/28, 1-H56/28, Ko-592, PhQA33 and LB-46 reduced the SMA. Maximum reduction of 65.6% was induced by PhQA33. In contrast, D,L(±) INPEA, D(-) INPEA, L(+) INPEA and pronethalol increased the SMA. Maximum increase of 27.4% was induced by L(+) (INPEA Table I).

TABLE II: Effect of some beta-adrenoceptor blocking compounds on pentobarbitone-induced anaesthesia in mice and their LD₅₀ values.

Compound	Dose* mg/kg ip	Mean anaesthetic time min ± SEM		% Pro- longation	ED ₁₀₀ mg/kg ip	'P' value	LD ₅₀ ± SEM mg/kg ip
		control (3)	test (4)				
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)
Propranolol	10		22 ± 6.9	47			132 ± 13.3
	20	15 ± 1.73	29 ± 7.7	93	23	<0.001	(106—158)
	40		42 ± 4.8	180			
Pronethalol	10		31 ± 6.3	34			
	20	23 ± 3.16	40 ± 3.5	73	30	<0.001	102 ± 8.6
	40		56 ± 2.8	143			(85—119)
	50		63 ± 7.5	174			
d-H56/28	5		26 ± 3.0	30			
	10	20 ± 1.14	31 ± 3.5	55	18	<0.001	76 ± 7.5
	20		41 ± 2.8	105			(61—91)
	40		61 ± 7.9	205			
1-H56/28	10		21 ± 4.5	5			
	20	20 ± 1.14	25 ± 3.6	25	47	<0.001	174 ± 16.1
	40		36 ± 5.2	80			(152—205)
	50		41 ± 5.5	105			



(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)
Ko-592	10		34 ± 3.8	6			
	20)		40 ± 3.8	25			
	40)	32 ± 4.68	59 ± 8.9	59	64	>0.05	151 ± 13.4
	50)		55 ± 7.8	72			(128-181)
	70		66 ± 7.0	106			
PhQA33	10		51 ± 7.5	59			
	20	32 ± 2.82	57 ± 6.8	78	33	<0.001	112 ± 9.5
	40		69 ± 8.8	115			(94-131)
	50		74 ± 9.5	131			
LB-46	10		21 ± 4.6	40			
	20	15 ± 1.73	26 ± 3.5	73	30	<0.001	166 ± 14.1
	40		36 ± 2.2	140			(138-194)
	50		41 ± 5.1	173			
DL(±)INPEA	40	23 ± 3.16	18 ± 1.4	-21	-	>0.05	186 ± 16.4 (154-218)
D(-)INPEA	40	28 ± 4.12	18 ± 2.8	-35	-	>0.05	178 ± 15.7 (147-209)
L(+)INPEA	40	23 ± 3.16	13 ± 1.1	-43	-	>0.01	174 ± 14.5 (145-202)

*n = 10 at each dose-step.

ED₁₀₀ : Dose causing a 100% increase in anaesthetic time.

'P' value was obtained by using Student's t test at the dose-step 40 mg/kg i p.

Numerals in parentheses denote the 95% confidence limits; Miller and Tainter (8).

Numerals preceded by minus signs denote % decrease in sleeping time.

Propranolol, pronethalol, d-H56/28, 1-H56/28, PhQA33 and LB-46 induced a statistically significant prolongation of the anaesthetic time. The increase caused by Ko-592 was insignificant ($P > 0.05$). Comparison of the ED₁₀₀ values indicated that d-H56/28 was the most potent compound in this respect. The findings are summarised in Table II. The INPEA compounds shortened the anaesthetic time; and of these L(+) INPEA induced a statistically significant decrease.

The LD₅₀ values are shown in Table II. The INPEA compounds induced a dose-dependent motor inco-ordination excitement and hyperactivity. With the other compounds the animals were sedated and were listless till terminal convulsions. With all the compounds, death was preceded by convulsions, marked increase in respiratory rate and exhaustion.

DISCUSSION

Grana and Sossi (5) studied the relationship between chemical structure and CNS effects of some beta-adrenoceptor antagonists. They inferred that compounds of the phenylethanol series like DCI, INPEA and sotalol (MJ-1999) were either stimulants or were devoid of any central activity, while the naphthylethanolamines and naphthoxypropanolamines depressed the central nervous system. The effect of beta-receptor antagonists included in this study as observed on SMA in mice does not support this viewpoint. Both the isomers of H56/28 and PhQA33 depress SMA, i.e. they have a propranolol-like effect, although they possess chemical structures in which the bicyclic ring has been replaced by the allylphenoxy and phenoxyphenoxy groups respectively. Thus, it seems, that the CNS-depressant activity is not restricted to the naphthoxy moiety in propranolol. If increase or decrease in SMA is considered as an evidence for CNS stimulant and depressant activity respectively (2,3,5) our finding that pronethalol enhances SMA stands in contrast to that of Grana and Sossi (5) who have categorised it as a central depressant. Similar contradictory findings have been obtained with DCI. Mnear and Rudzik (8) reported DCI to possess CNS-stimulant activity, while Hermansen (6) observed a depressant effect. The inability of INPEA to decrease SMA is in accordance with the findings of previous workers (6, 10). INPEA and its optical isomers exhibited a mild CNS-stimulant action. The dextro-isomer of H56/28 is devoid of beta-blocking activity (1). However, both the isomers of H56/28 decreased SMA. This corroborates the findings of Leszkovszky and Tardos (7), Murmann *et al.* (10) and Hermansen (6) who observed a lack of correlation between beta-blocking and CNS-depressant activity.

Almost a similar categorisation of the ten beta-receptor antagonists into stimulants and depressants of the CNS is evident from the results obtained in the pentobarbitone induced anaesthetic test and the acute intraperitoneal toxicity studies. The only exception is pronethalol which prolonged hypnosis and thus exhibited opposite actions in the two test-procedures. It may be interpreted to mean that modification of barbiturate anaesthesia is not a firm evidence for stimulant or depressant actions of a compound on the CNS. It is possible that potentiation by pronethalol of pentobarbitone induced anaesthesia is independent of its CNS-stimulant action, and is attributable to factors like interference with enzymatic breakdown of the barbiturate or hypothermia (6). However, no direct evidence in support of this viewpoint is available or adduced in the present study.

In the assessment of the central nervous effects of drugs, the dose employed is important, as in high doses compounds exhibit central effects which are their toxic manifestations. According to Ther (11) an effect becomes significant if attained with a dose of 1/2 to 1/5th of the LD₅₀ i.e. the ratio of LD₅₀ : ED₁₀₀ falling between 2 and 5. This ratio reckoned

for propranolol, pronethalol, d-H56/28, l-H56/28, Ko-592, PhQA33 and LB-46 indicate that all of them had a significant CNS-depressant action. The INPEA compounds failed to potentiate barbiturate-induced anaesthesia.

ACKNOWLEDGEMENTS

Thanks are due to the University of Rajasthan for permission to publish this work and to Shri P. S. Gaur for technical assistance. The generous gift of the following drugs is gratefully acknowledged: propranolol from Imperial Chemical Industries, Cheshire; isomers H56/28 from A. B. Hassle, Goteberg; LB-46 from Sandoz Limited, Basle; PhQA33 from Pharmacia AS, Vanlose, Denmark; Ko-592 from Boehringer Ingelheim, West Germany; and isomers or INPEA from Selvi & Company, Milano.

REFERENCES

1. Ablad, B., M. Brogard and L. Ek. Pharmacological properties of H 56/28 - a beta-adrenergic receptor antagonist. *Acta pharmac. tox.*, 25 (suppl. 2) : 9-40, 1967.
2. Boissier, J.R. and P. Simon. Evaluation of experimental techniques in the psychopharmacology of emotion. *Ann. N.Y. Acad. Sci.*, 159 : 898-914, 1969.
3. Dews, P.B. The measurement of the influence of drugs on voluntary activity in mice. *Br. J. Pharmacol.*, 8 : 46-48, 1953.
4. Fitzgerald, J.D. Propranolol-induced depression. *Br. Med. J.*, 2 : 372-373, 1967.
5. Grana, E. and D. Sossi. Ricerche sull' attivata' centrale di composti ad attivata' beta simpaticolita. *J. Farmaco Ed Sc.*, 22 : 582-589, 1967.
6. Hermansen, K. Effect of different beta-adrenergic receptor blocking agents on hexobarbital-induced narcosis in mice. *Acta pharmac. tox.*, 27 : 453-460, 1969.
7. Leszkovszky, G. and L. Tardos. Some effects of propranolol on the central nervous system. *J. Pharm. Pharmacol.*, 17 : 518-520, 1965.
8. Mennear, J.H. and A.D. Rudzik. The effect of alpha and beta adrenergic blockade on the lethality of amphetamine in aggregated mice. *Life Sci.*, 4 : 1425-1432, 1965.
9. Miller, L.C. and M.L. Tainter. Estimation of the ED₅₀ and its error by means of logarithmic-probit graph paper. *Proc. Soc. Exp. Biol. Med.*, 57 : 261-264, 1944.
10. Murmann, W., K. Almirante and M. Sacconi-Guelfi. Central nervous system effects of four beta-adrenergic receptor blocking agents. *J. Pharm. Pharmacol.*, 18 : 317-318, 1966.
11. Ther, L. Assessment of central activity. In : *Methods in Drug Evaluation*. Edited by Mantegazza, and Piccinini, F., Amsterdam, North-Holland Publishing Co. P 199, 1966.
12. Waal, H.J. Propranolol-induced depression. *Br. Med. J.*, 2 : 50, 1967.